Astellas Pharma

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 11, 2024

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, February 29, 2024

We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.

Key Points: 
  • We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.
  • R&D Expenses: Research and development expenses were $97.1 million for 2023, as compared to $80.3 million for 2022.
  • G&A Expenses: General and administrative expenses were $36.5 million for 2023, as compared to $32.9 million for 2022.
  • Net Loss: Net loss was $100.8 million for 2023, as compared to net loss of $107.5 million for 2022.

Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer

Retrieved on: 
Thursday, March 7, 2024

MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical development executive in respiratory medicine and orphan diseases. This appointment and the recent addition of microbiologist and clinical diagnostics expert Chris Polage, MD, as Medical Director, significantly bolster the company's clinical development expertise in pulmonary infectious diseases and medical microbiology. 

Key Points: 
  • MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer.
  • "Paul's development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization," said Nate Stasko, Chief Executive Officer at Vast Therapeutics.
  • "It is an amazing opportunity to join a company with an accepted IND for a novel treatment modality that shows promising efficacy against chronic infections caused by Pseudomonas aeruginosa and non-tuberculosis mycobacteria," commented Paul Bruinenberg, Chief Medical Officer at Vast Therapeutics.
  • Most recently, Dr. Bruinenberg served as the Senior Medical Officer of the TB Alliance leading clinical development against mycobacterial infections.

SDP Announces Their Annual Conference April 15-19, 2024

Retrieved on: 
Wednesday, March 6, 2024

LOS GATOS, Calif., March 6, 2024 /PRNewswire/ -- The Society of Decision Professionals (SDP) is pleased to announce its 30th Annual Conference taking place April 16-18 in Arlington, VA. Their 2024 conference, "Effective Decision-Making in a Dynamic World, " promises to be a transformative experience for professionals seeking to enhance their decision-making skills.

Key Points: 
  • LOS GATOS, Calif., March 6, 2024 /PRNewswire/ -- The Society of Decision Professionals (SDP) is pleased to announce its 30th Annual Conference taking place April 16-18 in Arlington, VA. Their 2024 conference, "Effective Decision-Making in a Dynamic World, " promises to be a transformative experience for professionals seeking to enhance their decision-making skills.
  • "We are thrilled to host our 30th-anniversary conference, where decision-makers from around the world can come together to explore innovative strategies and insights," said Terry Karner and Neil Hamlett, Co-Chairs of the conference.
  • The conference features a lineup of renowned speakers, with Dave Snowden, founder and Chief Scientific Officer of the Cynefin Co. as the keynote speaker, kicking off the event.
  • The SDP's Annual Conference is a must-attend event for decision professionals looking to expand their knowledge, learn from industry experts, and network with peers.

Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Retrieved on: 
Sunday, March 3, 2024

In Japan, two Phase 3 clinical studies are underway.

Key Points: 
  • In Japan, two Phase 3 clinical studies are underway.
  • We are excited the STARLIGHT Phase 3 clinical studies are underway, bringing us one step closer to making this novel, nonhormonal treatment option available in Japan for women experiencing VMS associated with menopause."
  • Dosing for the STARLIGHT Phase 3 clinical studies was determined based on available global data, including the STARLIGHT Phase 2b study ( NCT05034042 ) that enrolled 147 patients and completed in 2022.
  • Primary results of STARLIGHT Phase 2b were presented at the Annual Meeting of the Japan Society for Menopause and Women's Health on Dec. 3, 2023.

Breakthrough 2024 Speaker Lineup Announced - Industry Experts to Discuss the Evolution of Life Sciences Through Technology, Automation, and Artificial Intelligence

Retrieved on: 
Wednesday, February 21, 2024

LONDON, Feb. 21, 2024 /PRNewswire/ -- ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, today revealed the speaker line-up for Breakthrough 2024, its annual industry event. Taking place from March 19-20 in London, England, Breakthrough 2024 will facilitate the brightest, forward-looking life sciences industry conversations and serve as the company's showcase where it will announce latest LifeSphere developments.  

Key Points: 
  • Taking place from March 19-20 in London, England, Breakthrough 2024 will facilitate the brightest, forward-looking life sciences industry conversations and serve as the company's showcase where it will announce latest LifeSphere developments.
  • A deep-dive into GenAI's potential role in R&D transformation, as envisioned by a major industry player
    Announcements of the very latest LifeSphere developments.
  • "Breakthrough 2024's content-rich program is designed to inspire and focus industry players in making their next moves as AI continues to evolve and disrupt," said Julie Springer , Chief Marketing Officer at ArisGlobal.
  • Breakthrough2024 will take place March 19-20 at the Leonardo Royal Hotel in London, UK.

Breakthrough 2024 Speaker Lineup Announced - Industry Experts to Discuss the Evolution of Life Sciences Through Technology, Automation, and Artificial Intelligence

Retrieved on: 
Wednesday, February 21, 2024

LONDON, Feb. 21, 2024 /PRNewswire/ -- ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, today revealed the speaker line-up for Breakthrough 2024, its annual industry event. Taking place from March 19-20 in London, England, Breakthrough 2024 will facilitate the brightest, forward-looking life sciences industry conversations and serve as the company's showcase where it will announce latest LifeSphere developments.  

Key Points: 
  • Taking place from March 19-20 in London, England, Breakthrough 2024 will facilitate the brightest, forward-looking life sciences industry conversations and serve as the company's showcase where it will announce latest LifeSphere developments.
  • A deep-dive into GenAI's potential role in R&D transformation, as envisioned by a major industry player
    Announcements of the very latest LifeSphere developments.
  • "Breakthrough 2024's content-rich program is designed to inspire and focus industry players in making their next moves as AI continues to evolve and disrupt," said Julie Springer , Chief Marketing Officer at ArisGlobal.
  • Breakthrough2024 will take place March 19-20 at the Leonardo Royal Hotel in London, UK.

Royalty Pharma Reports Q4 and Full Year 2023 Results

Retrieved on: 
Thursday, February 15, 2024

In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.

Key Points: 
  • In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.
  • Royalty Pharma began repurchasing its Class A ordinary shares in April 2023 under a $1.0 billion multi-year share repurchase program.
  • During the fourth quarter of 2023, Royalty Pharma announced new transactions of up to $1.6 billion.
  • Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2023 results today at 8:00 a.m., Eastern Time.

Iktos opens a subsidiary in Japan and entrusts its management to Hideyoshi Fuji

Retrieved on: 
Wednesday, February 14, 2024

Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.

Key Points: 
  • Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.
  • Hideyoshi Fuji has been appointed Representative Director of Iktos K.K., and Vice-President, Japan Business Development and Operations.
  • Hideyoshi, 42, spent 13 years at Astellas Pharma Inc. (2009-2021) as an expert in computational chemistry and chemoinformatics.
  • After his career with Astellas Pharma, Hideyoshi became an entrepreneur in 2022 and supported business development and marketing efforts in Japan for overseas software companies.

LAPIX Therapeutics Strengthens Board of Directors with Appointments of Pharmaceutical Industry Veterans Henry A. McKinnell, Ph.D., Anthony Gibney, and Francisco Leon, MD, Ph.D.

Retrieved on: 
Wednesday, February 7, 2024

He is a member of the boards of directors of Nexcella and the Science and Technology in Society Forum.

Key Points: 
  • He is a member of the boards of directors of Nexcella and the Science and Technology in Society Forum.
  • His dual expertise in finance and biotech uniquely positions his insights at the intersections of financial strategy and operational expertise.
  • Joining the Board as a Board Observer, Dr. Leon will lend his significant expertise in clinical immunology, translational medicine and as a successful drug developer.
  • "I am honored to welcome new colleagues to the board,” added Dr. Fathallah.